लोड हो रहा है...
Effect of Erythropoiesis-Stimulating Agent Policy Decisions on Off-Label Use in Myelodysplastic Syndromes
BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia associated with myelodysplastic syndromes (MDS) as an off-label indication. In early 2007, the U.S. Food and Drug Administration (FDA) released safety alerts and mandated label changes, and the Centers for Medicare...
में बचाया:
| में प्रकाशित: | Medicare Medicaid Res Rev |
|---|---|
| मुख्य लेखकों: | , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Centers for Medicare & Medicaid Services
2014
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4254334/ https://ncbi.nlm.nih.gov/pubmed/25485173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5600/mmrr.004.04.a02 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|